Skip to main content
NKTX
NASDAQ Life Sciences

Nkarta Finalizes $100M At-The-Market Offering Agreement with Stifel

Analysis by Wiseek AI
Sentiment info
Negative
Importance info
7
Price
$2.13
Mkt Cap
$151.293M
52W Low
$1.31
52W High
$2.81
Market data snapshot near publication time

Summary

Nkarta, Inc. has entered into a sales agreement with Stifel, Nicolaus & Company, Incorporated to establish an At-The-Market (ATM) offering program, allowing the company to sell up to $100 million of its common stock.


Key Events

  • Establishes $100M At-The-Market Offering

    Nkarta, Inc. entered into a Sales Agreement with Stifel, Nicolaus & Company, Incorporated to sell up to $100 million of its common stock through an At-The-Market (ATM) offering program.

  • Follows Prior S-3 Disclosure

    This agreement formalizes the ATM program previously disclosed in the company's S-3 registration statement filed on March 25, 2026, which included an ATM prospectus supplement.

  • Potential for Significant Dilution

    The program allows for the sale of shares representing a substantial portion of the company's current market capitalization, indicating significant potential dilution for existing shareholders.


Analysis

This 8-K formalizes the sales agreement for the $100 million At-The-Market (ATM) offering program that Nkarta, Inc. previously disclosed in its S-3 registration statement filed on March 25, 2026. While the potential for this significant capital raise was already known, this filing confirms the operational details, including the appointment of Stifel as the sales agent and a commission of up to 3%. The program allows the company to sell shares from time to time, providing flexibility for future capital needs. Given the company's market capitalization, the potential sale of up to $100 million in common stock represents substantial potential dilution for existing shareholders, creating an overhang on the stock. Investors should monitor the pace and pricing of any future sales under this program.

At the time of this filing, NKTX was trading at $2.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $151.3M. The 52-week trading range was $1.31 to $2.81. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NKTX - Latest Insights

NKTX
May 12, 2026, 4:09 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $3.10
Real-time Price: $2.86 info
Change: -$0.240 (-8%) info
Market Cap: $204.62M info
NKTX
May 12, 2026, 4:04 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.28
Real-time Price: $2.86 info
Change: -$0.420 (-13%) info
Market Cap: $204.62M info
NKTX
Apr 15, 2026, 5:21 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $2.41
Real-time Price: $2.86 info
Change: +$0.450 (+19%) info
Market Cap: $204.62M info
NKTX
Apr 03, 2026, 5:29 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $2.32
Real-time Price: $2.86 info
Change: +$0.540 (+23%) info
Market Cap: $204.62M info
NKTX
Mar 25, 2026, 5:55 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.13
Real-time Price: $2.86 info
Change: +$0.730 (+34%) info
Market Cap: $204.62M info
NKTX
Mar 25, 2026, 5:23 PM EDT
Filing Type: S-3
Importance Score:
8
Price at Filing: $2.11
Real-time Price: $2.86 info
Change: +$0.750 (+36%) info
Market Cap: $204.62M info
NKTX
Mar 25, 2026, 4:07 PM EDT
Filing Type: 10-K
Importance Score:
7
Price at Filing: $2.10
Real-time Price: $2.86 info
Change: +$0.7554 (+36%) info
Market Cap: $204.62M info
NKTX
Mar 25, 2026, 4:04 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.13
Real-time Price: $2.86 info
Change: +$0.730 (+34%) info
Market Cap: $204.62M info